Novartis to License Google "Smart Lens" Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Novartis to License Google "Smart Lens" Technology



Novartis’ eye care division, Alcon, has entered into an agreement with a division of Google to in-license its "smart lens" technology for all ocular medical uses. The agreement with Google[x], a specialized team within Google, provides Alcon with the opportunity to develop and commercialize Google's "smart lens" technology with the potential to further enhance Alcon's pipeline. The transaction remains subject to anti-trust approvals.

Under the agreement, Google[x] and Alcon will collaborate to develop a "smart lens" that has the potential to address ocular conditions. The smart lens technology involves non-invasive sensors, microchips, and other miniaturized electronics, which are embedded within contact lenses.

Novartis' interest in this technology is currently focused in two areas. One, helping diabetic patients manage their disease by providing a continuous, minimally invasive measurement of the body's glucose levels via a "smart contact lens" which is designed to measure tear fluid in the eye and connects wirelessly with a mobile device; and two, for people living with presbyopia who can no longer read without glasses, the "smart lens" has the potential to provide accommodative vision correction to help restore the eye's natural autofocus on near objects in the form of an accommodative contact lens or intraocular lens as part of the refractive cataract treatment.

Source: Novartis

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here